Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Piper Sandler Maintains Overweight on Pulmonx, Lowers Price Target to $13

Piper Sandler Maintains Overweight on Pulmonx, Lowers Price Target to $13

Piper Sandler analyst Jason Bednar maintains Pulmonx (NASDAQ:LUNG) with a Overweight and lowers the price target from $25 to $13.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Piper Sandler analyst Jason Bednar maintains Pulmonx (NASDAQ:LUNG) with a Overweight and lowers the price target from $25 to $13.

Analyst Ratings

4 Analysts Have This to Say About Corporate Office Props Tr

By Benzinga Insights

June 13, 10:00 AM

Within the last quarter, Corporate Office Props Tr (NYSE:OFC) has observed the following analyst ratings: Bullish Somewhat Bullish…

OFC

These 2 Analysts Just Raised Their Expectations For NVDIA – Here’s Why

By Anusuya Lahiri

August 17, 11:15 AM

Nvidia Corp (NASDAQ: NVDA) stock remains the cynosure of analyst attent

NVDA

News

A Look Into Consumer Defensive Sector Value Stocks

By Benzinga Insights

December 1, 10:39 AM

Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies…

Tech Giants Stand To Profit The Most From The Data Privacy Revolution, Beringer Capital Says

By Piero Cingari

May 27, 10:00 AM

Apple, in a shot heard around the world, ripped apart the accepted model of tech advertising when it enabled unprecedented consumer privacy features earlier this decade.

AAPL

Piper Sandler Maintains Overweight on Pulmonx, Lowers Price Target to $13

Related Posts

4 Analysts Have This to Say About Corporate Office Props Tr

These 2 Analysts Just Raised Their Expectations For NVDIA – Here’s Why

A Look Into Consumer Defensive Sector Value Stocks

Tech Giants Stand To Profit The Most From The Data Privacy Revolution, Beringer Capital Says